化疗是中晚期肺癌最主要的治疗手段，而化疗药物的剂量限制性毒性是其疗效的瓶颈。我们前期通过临床实践构建的益气养阴填髓法可减轻化疗后骨髓抑制，提高瘤体稳定率，同时可改善肺部症状，其动物实验和临床观察结果与中医“金水相生”理论吻合，但其中减毒增效机制还不清楚，对于肺癌治疗中存在的这种“滋肾填髓→补肺抑瘤”机理需要研究。TGF-β1/Smad信号通路可影响肺癌的发生、发展，同时对骨髓造血干细胞及机体免疫反应也有调控作用。课题拟通过体内外实验，从TGF-β1/Smad信号通路的基因和蛋白表达角度阐明其对非小细胞肺癌化疗减毒增效的分子药理机制，以及对肺癌组织、骨髓造血组织的双重调控作用机制，并通过对其剂量-效应关系进行研究，计算量效关系的曲线模型以验证“滋肾填髓→补肺抑瘤”的假说，揭示肺癌治疗中存在“金水相生”的机理，为找到针对非小细胞肺癌化疗具有减毒增效作用的治疗方法提供科学依据。

Chemotherapy is the main treatment of advanced lung cancer. The dose-limiting toxicity of chemotherapy drugs is the bottleneck of its efficacy. Our preliminary studies built through clinical practice proved that Supplementing Qi, Nourishing Yin and Filling Marrow (SQNYFM) can reduce bone marrow suppression after chemotherapy, increase the stability of the rate of tumor, and improve pulmonary symptoms. The results of animal experiments and clinical observations coincide with traditional Chinese medicine theory of mutual promotion between lung and kidney.but,the mechanism of attenuation and synergic with SQNYFM is unclear and we need to study for the mechanism of this exists in the treatment of lung cancer from Nourishing kidney and Filing marrow(NKFM) to reinforcing lung and controlling tumor(RLCT).TGF-β1/Smad signaling pathway can affect the occurrence and development of lung cancer, the bone marrow hematopoietic stem cells and the immune response regulation. This study will be completed by vivo and vitro experiments from angle of TGF-β1/Smad signaling pathway in gene and protein expression. The purpose of this study was to clarify the molecular pharmacological mechanism of attenuation and synergic for non-small cell lung cancer after chemotherapy, to explore dual control effects of lung tissue and bone marrow hematopoietic tissue, to testify the hypothesis of NKFM and RLCT through the dose-effect relationship research and its dose-effect relationship curve model calculation，to reveal the mechanism of mutual promotion between lung and kidney in the treatment of lung cancer, to find a effective attenuation and synergic treatment method providing a scientific basis in non-small cell lung cancer after chemotherapy.